PermaLife Cell Culture Bag

Closed Solicitation Posted

Solicitation number
19006498
Agency
National Institutes of Health Department of Health and Human Services
Responses due
Set-aside
No set-aside

Opportunity facts

Contract number
75N90019P00271 Federal contract award
NAICS code
334516 Analytical Laboratory Instrument Manufacturing
PSC
Not on record
Place of performance
6707 Democracy Blvd. Suite 106 Bethesda, Maryland 20892, United States

Notice details come from SAM.gov. Updated .

Notice text

This is a notice of intent, not a request for a quotation. A solicitaiton document will not be issued and quotations will not be requested.
The Government intends to award a fixed price purchase order to Origen Biomedical, Inc., Austin, Texas 78744.
The Department of Transfusion Medicine (DTM) at the National Institutes of Health (NIH) Clinical Center (CC), Bethesda, MD has a requirement to procure the supplies listed below:
1. PL30-2G Permalife Cell Culture Bag 30ml 400 each
2. PL07-2G Permalife Cell Culture Bag 7ml 20 each
3. PL120-2G Permalife Cell Culture Bag 120ml 130 each
4. PC2-B Protective Cap for female luer 100 each
5. PL240-2G Permalife Cell Culture Bag 240 50 each
6. PL325-2G Permalife Cell Culture Bag 325ml 150 each
7. PL70-2G Permalife Cell Culture Bag 70ml 60 each
The Center for Cellular Engineering (CCE), Department of Transfusion Medicine, NIH Clinical Center (CC) is an AABB accredited cellular therapy laboratory whose central mission is to provide services to the NIH Institutes to support their intramural clinical trials. These services include (1) performing research aimed at development, evaluation and validation of new manufacturing processes for cellular therapies (2) manufacture of cellular therapy products for approved clinical trials. The majority of these trials are early phase (l/ll) trials not intended to result in the development of a commercial product. CCE produces clinical therapies from cells collectd from NIH CC patients and healthy donors. The product manufactured in this project by the laboratory is retinal pigment epithelium (RPE) generated from patient's blood cells. this product (RPE) will be used to treat age-related manufacturing process of this product. RPE will be manufactured using US Food and Drug Administration (FDA) guidelines for good manufacturing practices (GMP). It will require review and approval for use as an investigational new drug (IND) by the FDA.
.

On GovTribe

Work this opportunity on GovTribe

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity